Published in J Clin Microbiol on February 01, 2012
Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009. Clin Infect Dis (2013) 1.78
Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugs. J Clin Microbiol (2012) 1.32
Concordance between molecular and phenotypic testing of Mycobacterium tuberculosis complex isolates for resistance to rifampin and isoniazid in the United States. J Clin Microbiol (2014) 1.19
Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugs. Antimicrob Agents Chemother (2013) 1.10
Integration of published information into a resistance-associated mutation database for Mycobacterium tuberculosis. J Infect Dis (2015) 1.06
Integrated microfluidic card with TaqMan probes and high-resolution melt analysis to detect tuberculosis drug resistance mutations across 10 genes. MBio (2015) 0.92
Challenges and controversies in defining totally drug-resistant tuberculosis. Emerg Infect Dis (2012) 0.78
Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother (2015) 0.75
Assessment of a 96-Well Plate Assay of Quantitative Drug Susceptibility Testing for Mycobacterium Tuberculosis Complex in China. PLoS One (2017) 0.75
Discordance across Phenotypic and Molecular Methods for Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates in a Low TB Incidence Country. PLoS One (2016) 0.75
The resurgence of tuberculosis: is your laboratory ready? J Clin Microbiol (1993) 11.70
MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE. Bull World Health Organ (1963) 9.26
Current practices in mycobacteriology: results of a survey of state public health laboratories. J Clin Microbiol (1993) 5.99
The 7H11 medium for the cultivation of mycobacteria. Am Rev Respir Dis (1968) 4.23
Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Laboratory Network: first round of proficiency testing. Int J Tuberc Lung Dis (1997) 3.37
Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J Clin Microbiol (2009) 3.08
Current status of mycobacterial testing in clinical laboratories. Results of a questionnaire completed by participants in the College of American Pathologists Mycobacteriology E survey. Arch Pathol Lab Med (1993) 2.89
Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994-1998. Int J Tuberc Lung Dis (2002) 2.79
Variation in proficiency testing performance by testing site. JAMA (1998) 2.73
Interlaboratory drug susceptibility testing of Mycobacterium tuberculosis by a radiometric procedure and two conventional methods. J Clin Microbiol (1985) 2.68
Multicenter evaluation of ethambutol susceptibility testing of mycobacterium tuberculosis by agar proportion and radiometric methods. J Clin Microbiol (2002) 2.12
The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect (2011) 1.97
Trends in tuberculosis--United States, 2008. MMWR Morb Mortal Wkly Rep (2009) 1.52
Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother (2009) 1.52
Results of the external quality assessment of Mycobacterium tuberculosis drug susceptibility testing in Russia, 2005-2007. Int J Tuberc Lung Dis (2009) 1.52
Trends in tuberculosis--United States, 2010. MMWR Morb Mortal Wkly Rep (2011) 1.51
Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int J Tuberc Lung Dis (2010) 1.38
[WHO sample survey on drug resistant tuberculosis in Zhejiang, China]. Zhonghua Jie He He Hu Xi Za Zhi (2000) 1.07
External quality control of Mycobacterium tuberculosis drug susceptibility testing: results of two rounds in endemic countries. Int J Tuberc Lung Dis (2008) 0.92
Proficiency testing of conventional drug susceptibility tests of Mycobacterium tuberculosis. Can J Microbiol (1987) 0.85
Identification of a Mycobacterium tuberculosis strain with stable, low-level resistance to isoniazid. J Clin Microbiol (2004) 0.82
Laboratory practices for diagnosis of tuberculosis--United States, 1994. MMWR Morb Mortal Wkly Rep (1995) 0.80
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med (2007) 33.18
Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep (2005) 8.91
Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet (2012) 6.78
Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep (2005) 6.45
Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis (2007) 6.41
Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2011) 4.55
Core functions and capabilities of state public health laboratories: a report of the Association of Public Health Laboratories. MMWR Recomm Rep (2002) 4.38
Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med (2013) 3.51
U.S. outpatient antibiotic prescribing, 2010. N Engl J Med (2013) 3.49
Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2009) 2.77
Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg Infect Dis (2002) 2.76
Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) disease. PLoS One (2010) 2.59
The State Public Health Laboratory System. Public Health Rep (2010) 2.48
ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother (2003) 2.31
Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J Infect Dis (2004) 2.29
Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of Neisseria meningitidis. J Clin Microbiol (2004) 2.20
Application of TaqMan low-density arrays for simultaneous detection of multiple respiratory pathogens. J Clin Microbiol (2011) 2.07
Tuberculosis among foreign-born persons in the United States: achieving tuberculosis elimination. Am J Respir Crit Care Med (2006) 2.03
Inactivation of Bacillus anthracis spores. Emerg Infect Dis (2003) 1.96
Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med (2004) 1.96
Risk factors for Buruli ulcer disease (Mycobacterium ulcerans Infection): results from a case-control study in Ghana. Clin Infect Dis (2005) 1.95
Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis (2009) 1.81
Increasing proportions of advanced pulmonary tuberculosis reported in the United States: are delays in diagnosis on the rise? Am J Respir Crit Care Med (2009) 1.78
Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States. Clin Infect Dis (2010) 1.76
Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev (2003) 1.65
Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. Psychooncology (2002) 1.64
Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization. J Immunol Methods (2008) 1.64
Outpatient antibiotic prescribing and nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003. Clin Infect Dis (2011) 1.63
One-year health assessment of adult survivors of Bacillus anthracis infection. JAMA (2004) 1.61
Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. Sex Transm Dis (2005) 1.58
National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis (2005) 1.55
Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene. Virology (2009) 1.51
Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prev Res (Phila) (2013) 1.50
Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa. PLoS One (2011) 1.38
National plan for reliable tuberculosis laboratory services using a systems approach. Recommendations from CDC and the Association of Public Health Laboratories Task Force on Tuberculosis Laboratory Services. MMWR Recomm Rep (2005) 1.31
Multidrug-resistant tuberculosis detection, Latvia. Emerg Infect Dis (2005) 1.28
Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis (2005) 1.27
Holiday spikes in pneumococcal disease among older adults. N Engl J Med (2009) 1.24
Distribution of lag-1 alleles and sequence-based types among Legionella pneumophila serogroup 1 clinical and environmental isolates in the United States. J Clin Microbiol (2009) 1.22
Estimating effect of antiviral drug use during pandemic (H1N1) 2009 outbreak, United States. Emerg Infect Dis (2011) 1.20
Incidence and severity of invasive Streptococcus pneumoniae, group A Streptococcus, and group B Streptococcus infections among pregnant and postpartum women. Clin Infect Dis (2011) 1.19
Implementation of a quality systems approach for laboratory practice in resource-constrained countries. AIDS (2005) 1.18
Tuberculosis serodiagnosis in a predominantly HIV-infected population of hospitalized patients with cough, Botswana, 2002. Clin Infect Dis (2004) 1.13
Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry. Breast Cancer Res (2009) 1.12
Trends and seasonal variation in outpatient antibiotic prescription rates in the United States, 2006 to 2010. Antimicrob Agents Chemother (2014) 1.11
Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis Rheum (2005) 1.11
Transmission network analysis to complement routine tuberculosis contact investigations. Am J Public Health (2006) 1.11
Mycobacterium tuberculosis transmission from human to canine. Emerg Infect Dis (2004) 1.07
Laboratory services in support of public health: a status report. Public Health Rep (2010) 1.04
Clinical research and development of tuberculosis diagnostics: moving from silos to synergy. J Infect Dis (2012) 1.03
In the treatment of tuberculosis, you get what you pay for... Am J Respir Crit Care Med (2004) 1.02
Presentation and outcomes of systemic non-Hodgkin's lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. Leuk Lymphoma (2006) 1.01
Risk of second primary colorectal cancer among colorectal cancer cases: a population-based analysis. J Carcinog (2011) 1.00
How valid is using cancer registries' data to identify acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma? Cancer Causes Control (2007) 0.99
Gender and race/ethnicity affect the cost-effectiveness of colorectal cancer screening. J Natl Med Assoc (2006) 0.99
Systems approach to improving antimicrobial susceptibility testing in clinical laboratories in the United States. J Clin Microbiol (2007) 0.94
Chest radiography for tuberculosis screening is back on the agenda. Int J Tuberc Lung Dis (2012) 0.94
Survival of distinct Asian groups among colorectal cancer cases in California. Cancer (2009) 0.94
Adenosquamous versus adenocarcinoma of the pancreas: a population-based outcomes analysis. J Gastrointest Surg (2010) 0.93
Competency Guidelines for Public Health Laboratory Professionals: CDC and the Association of Public Health Laboratories. MMWR Surveill Summ (2015) 0.92
Multidrug-resistant tuberculosis drug susceptibility and molecular diagnostic testing. Am J Med Sci (2013) 0.90
Global laboratory initiative tool for a stepwise process towards tuberculosis laboratory accreditation. Int J Tuberc Lung Dis (2012) 0.89
Rapidly building global health security capacity--Uganda demonstration project, 2013. MMWR Morb Mortal Wkly Rep (2014) 0.88
Prevalence of sequence types among clinical and environmental isolates of Legionella pneumophila serogroup 1 in the United States from 1982 to 2012. J Clin Microbiol (2013) 0.88
A unique gender difference in early onset melanoma implies that in addition to ultraviolet light exposure other causative factors are important. Pigment Cell Melanoma Res (2012) 0.87
Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 0.87
Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis (2005) 0.87
Quality of life, characteristics and survival of patients with HIV and lymphoma. Qual Life Res (2010) 0.86
Highly active antiretroviral therapy is associated with improved survival among patients with AIDS-related primary central nervous system non-Hodgkin's lymphoma. Curr HIV Res (2006) 0.85
Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment. Laryngoscope (2003) 0.84
More on U.S. outpatient antibiotic prescribing, 2010. N Engl J Med (2013) 0.84
Accuracy and precision of Legionella isolation by US laboratories in the ELITE program pilot study. Water Res (2011) 0.84
The AGREE II instrument is helpful for creation of National Academy of Clinical Biochemistry laboratory medicine practice guidelines. Clin Chem (2012) 0.83
The evolving Public Health Laboratory System. Public Health Rep (2010) 0.83
Trends in laboratory test volumes for Medicare Part B reimbursements, 2000-2010. Arch Pathol Lab Med (2013) 0.83
Improved survival and chemotherapy response among patients with AIDS-related non-Hodgkin's lymphoma receiving highly active antiretroviral therapy. Hematol Oncol (2006) 0.82
Identification of a Mycobacterium tuberculosis strain with stable, low-level resistance to isoniazid. J Clin Microbiol (2004) 0.82
Childhood vaccinations and risk of asthma. Pediatr Infect Dis J (2002) 0.82
Strengthening global health security capacity--Vietnam demonstration project, 2013. MMWR Morb Mortal Wkly Rep (2014) 0.82
Tuberculosis transmission in nontraditional settings: a decision-tree approach. Am J Prev Med (2005) 0.80
The burden and severity of illness due to 2009 pandemic influenza A (H1N1) in a large US city during the late summer and early fall of 2009. Am J Epidemiol (2012) 0.79
Assessment of Etest as an alternative to agar dilution for antimicrobial susceptibility testing of Neisseria gonorrhoeae. J Clin Microbiol (2014) 0.79
Discordance in Mycobacterium tuberculosis rifampin susceptibility. Emerg Infect Dis (2012) 0.79
Assessment of laboratory performance of nucleic acid amplification tests for detection of Mycobacterium tuberculosis. J Clin Microbiol (2003) 0.78
Challenges and controversies in defining totally drug-resistant tuberculosis. Emerg Infect Dis (2012) 0.78
Report from the CDC. Awareness of perinatal group B streptococcal infection among women of childbearing age in the United States, 1999 and 2002. J Womens Health (Larchmt) (2003) 0.76
Management of latent tuberculosis infection in immigrants. N Engl J Med (2003) 0.75
Differential West Nile fever ascertainment in the United States: a multilevel analysis. Am J Trop Med Hyg (2010) 0.75
Evaluation and epidemiological research in tuberculosis control: linking medical care and public health. Mayo Clin Proc (2004) 0.75
Declines in Opioid Prescribing After a Private Insurer Policy Change - Massachusetts, 2011-2015. MMWR Morb Mortal Wkly Rep (2016) 0.75
HIV-1 antiretroviral resistance testing laboratories. Clin Lab Sci (2002) 0.75
Trends in tuberculosis reported from the Appalachian region: United States, 1993-2005. J Rural Health (2008) 0.75
A Conceptual Framework for Allocation of Federally Stockpiled Ventilators During Large-Scale Public Health Emergencies. Health Secur (2016) 0.75
Can a marker be a surrogate for development of cancer, and would we know it if it exists? Recent Results Cancer Res (2005) 0.75
Potentially Preventable Deaths Among the Five Leading Causes of Death - United States, 2010 and 2014. MMWR Morb Mortal Wkly Rep (2016) 0.75